Assessing CareDx (CDNA) Valuation After Positive AlloHeme Clinical Validation Results

Simply Wall St

Sun, February 15, 2026 at 5:06 AM GMT+9 3 min read

In this article:

CDNA

+2.77%

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Why the AlloHeme data point matters for CareDx (CDNA)

CareDx (CDNA) has put its AlloHeme test in the spotlight after releasing pivotal clinical validation data showing earlier, highly sensitive relapse detection in acute myeloid leukemia and myelodysplastic syndromes following allogeneic hematopoietic cell transplantation.

See our latest analysis for CareDx.

The AlloHeme updates and upcoming investor webcast arrive after a mixed share price picture, with a 90 day share price return of 23.19% alongside a 1 year total shareholder return of 19.88% and a 5 year total shareholder return of 76.92%.

If AlloHeme piques your interest in how AI is reshaping diagnostics, it could be worth scanning a wider set of opportunities using our screener for 25 healthcare AI stocks.

With CareDx trading at $19.63, sitting at a 17% discount to the average analyst price target and an intrinsic value estimate implying even more upside, is the recent AlloHeme news a genuine entry point, or is future growth already reflected?

Most Popular Narrative: 14.7% Undervalued

With CareDx closing at $19.63 against a most followed fair value estimate of $23.00, the current price sits below what that narrative assumes, and it leans heavily on specific growth and profitability projections to get there.

The launch of AI-driven diagnostics like AlloSure Plus and integration into electronic health record systems (e.g., EPIC), positions CareDx to benefit from the broader adoption of precision medicine and personalized diagnostics, likely boosting adoption rates, aiding reimbursement, and ultimately supporting net margin improvements.

Read the complete narrative.

Curious what kind of revenue trajectory and margin profile are being baked into that $23.00 fair value, and how rich the future earnings multiple needs to be to make the math hold up? The most followed narrative sets out a detailed path that connects testing volumes, payer coverage and profitability assumptions into a single valuation story. It is worth seeing exactly which levers matter most in that model.

Result: Fair Value of $23 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story can change quickly if draft LCD policies tighten reimbursement, or if bundled payments and frequency limits hit AlloSure and HeartCare volumes harder than expected.

Find out about the key risks to this CareDx narrative.

Another Angle On CareDx’s Valuation

The narrative you just read leans on future earnings and implied P/E assumptions. Using today’s actual P/E of 14.3x tells a more complicated story. CareDx looks inexpensive next to peers at 46.5x and the wider US Biotechs group at 22.1x, yet expensive versus its fair ratio of 6.1x. Our model suggests the market could move toward that level over time. Is the current price a bargain relative to other stocks in the space, or is the gap to that fair ratio a warning sign about valuation risk?

Story Continues  

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:CDNA P/E Ratio as at Feb 2026

Build Your Own CareDx Narrative

If you look at the numbers and reach a different conclusion, or prefer to trust your own work, you can build a customized view in minutes by starting with Do it your way.

A great starting point for your CareDx research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one company, you miss the chance to spot other compelling setups that may better match your risk tolerance, income needs or growth goals.

Target potential mispricing by scanning our list of 53 high quality undervalued stocks that pair quality fundamentals with prices that look out of sync with underlying business strength.

Strengthen your focus on financial resilience by checking companies in the solid balance sheet and fundamentals stocks screener (44 results) that prioritize robust balance sheets and fundamentals.

Hunt for earlier stage stories by reviewing the 28 elite penny stocks with strong financials that still clear key financial quality filters rather than relying on hype alone.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CDNA.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info